Guggenheim downgraded Neumora Therapeutics (NMRA) to Neutral from Buy. with no price target following yesterday’s announcement that Johnson & Johnson (JNJ) is discontinuing its Phase 3 VENTURA program testing aticaprant as an adjunctive treatment for major depressive disorder due to insufficient efficacy. Aticaprant’s failure in MDD coming after Neumora’s KOASTAL-1 failure with navacaprant “further weakens our conviction” on the validity of this mechanism of action in this indication, says the analyst, who has “limited confidence” on the potential success of navacaprant in MDD at this point.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Cautious Hold Rating on Neumora Therapeutics Amid Efficacy Concerns and Clinical Trial Setbacks
- Neumora Therapeutics downgraded to Hold from Buy at Stifel
- Strategic Adjustments and MDD Focus Drive Buy Rating for Neumora Therapeutics Amid Study Delays
- Neumora Therapeutics price target lowered to $18 from $30 at H.C. Wainwright
- Neumora Therapeutics Reports 2024 Financial Results and Updates
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue